Market Research Blog

Rapidly growing demand for homecare devices as a result of a paradigm shift from conventional clinics to in-house, non-invasive energy treatments is prominently responsible for healthy revenue growth projections for homecare dermatology energy-based devices.

Technological advancements in these devices are widening their application base, thereby pushing the rate of adoption further at a global level. Another strong push factor associated with homecare dermatology energy-based devices includes their availability as the OTC products.

• Product type analysis of market landscape reveals that laser and IPL (intense pulsed light) equipment are enjoying the highest sales, whereas LED equipment is projected to emerge as the most attractive segment in homecare dermatology energy based devices space in the near future.
• Hair removal and acne, followed by wrinkles treatment, are reportedly the most extensively sought after applications of homecare dermatology energy based devices.
• E-commerce dominates all other distribution channels, according to the report. Hyper markets and super markets also remain among the preferred channels for product distribution.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7699

A Bird’s Eye View of the Global Landscape

“The global market for homecare dermatology energy based devices is a highly consolidated landscape, wherein the top two players collectively account for around 60% share of the market revenue. Koninklijke Philips, with more than a third of the market value share, secures the top position with its extensive portfolio of intense pulsed light devices used for hair removal,” explains a senior research analyst while offering the inclusions of the company’s recent report on the global homecare dermatology energy based devices market.

Adding further to the information about the market competition, the analyst says, “A majority of companies are prioritizing product innovations in LED, IR, and lasers segments. Moreover, a large number of market players are taking efforts for extended product reach through retail partnerships, in addition to NPD for a wider application base. Companies are also observed to be focusing on collaborations and acquisitions to reshape their product distribution strategy for better profitability”.

FDA Approvals Are Relatively Easy

Relatively easy and faster FDA approvals for homecare dermatology energy based devices are driving improved appearance of these devices in tandem with the latest handheld gadgets, which prominently curtail the need for frequent visits to professional cosmetic treatment centers.

A recent example includes FDA clearance for Titan – the anti-aging device launched by Skinovations Inc. later in 2017.

On a similar line, North American and European markets for homecare dermatology energy based devices are witnessing remarkable adoption in recent years. FMI identifies a slew of business expansion opportunities in the aforementioned regions for manufacturers of homecare dermatology energy based devices.

Moreover, growing R&D efforts as manufacturers in the US zoom in on the production quality, is likely to shape the performance of North America’s market for homecare dermatology energy based devices.

Combination of Technologies for Better Treatment Output

Making the most of the best attributes of LED and lasers technologies, a new trend among manufacturers now involves the combination of both the technologies for manufacturing homecare dermatology energy based devices. While these devices are claimed to be effectively reducing fine lines and improving skin tone with LED, lasers enable them to be highly target specific. A recent example is of YA-MAN’s RF Beaute Photo PLUS.

Increasing researches conducted on monoclonal antibodies are driving demand for protein A resin. Since the commercialization of the first therapeutic monoclonal antibody in 1986, till May 2021, around 100 monoclonal antibody products have been approved by the U.S. FDA and European Medical Agency for the treatment of various diseases such as cancer.

Monoclonal antibody therapy for the treatment of mild to moderate COVID-19 in patients has also been approved by the FDA under Emergency Use Authorization (EUA).

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1720

Studies on monoclonal antibodies have indicated that more monoclonal antibody therapies are in the process of getting FDA approval and can be marketed in the near future to cater to rising demand in the global life sciences industry. Thus, increasing research on monoclonal antibodies (mAb) is expected to fuel the demand and utilization of protein A resin for purification and precipitation purposes.

For the purification of monoclonal antibodies (mAb), different technologies are available which includes membrane chromatography, mixed chromatography, and aqueous two-phase extractions (ATPS). However, protein A resin holds the top position for the purification of mAbs.

With many industries facing issues of leaching of ligand and resistance during the commercialization of monoclonal antibodies (mAbs), the availability of next-generation protein A resins with improved purification conditions, such as alkaline-stability, and with very low ligand leaching, is expected to increase the production and throughput demand for protein therapeutic processes.

Furthermore, in June 2018, Purolite Life Sciences launched a novel next-generation Protein A agarose resin, Praesto Jetted A50. GE Healthcare, in 2017, introduced a next-generation protein A resin, MabSelect PrismaA, which was designed to enable biopharma manufacturers to improve their mAb purification capacity by up to 40% over GE Healthcare’s existing protein A affinity medium. These product launches are expected give tailwinds to growth registered in the market.

Such developments not only strengthen the company’s existing portfolio but also help to increase their presence at the regional as well as global level.

Key Takeaways from Protein A Resin Study

• By product, the natural protein A resin hold the maximum share of 62.8% in 2021. Natural protein A is derived from a bacterial cell of the staphylococcus aureus species and mainly used in the purification of monoclonal antibodies.
• By matrix, the agarose based matrix of protein A resin account for 85.8% of the market share in 2021 indicating the highest demand, offering high binding specificity when in comparison to other matrices and are widely used for the attachment of ligands that bind proteins.
• By application, the antibody purification of protein A resin segment will account for 74.8% of the market share in 2021.
• By end user, the biopharmaceutical manufacturers will account for 79.2% of the market share in 2021.
• By region, North America held the largest share of 35.7% of the global protein A resins market in 2021.
• The U.S. will emerge as a leading market in North America, while growth registered in Europe will be spearheaded by Germany and the U.K.

“Increasing demand of protein A Resins for biologics production including monoclonal antibody and biosimilars is expected to drive the demand of protein a resin over the decade. To capitalize on existing opportunities, market players are expected to push investment towards product launches and research initiatives,” says the FMI Analyst

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1720

Who is Winning?Some of the leading manufacturers of protein A resin market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

• In August 2021, Danaher Corporation acquired Aldevron and stated that Aldevron will work as a stand-alone operating firm and brand within the life sciences segment of Danaher to provide a vast range of custom biologic services, including plasmid DNA production, mRNA production, and antibody development.
• On 11 February 2021, Thermo Fisher Scientific Inc. started the online offering of its essential Thermo Scientific Dionex Easion and Thermo Scientific Dionex Aquion Ion Chromatography (IC) systems through easy online ordering.  This step was undertaken in order to reduce the in-person transaction during the pandemic.
• In October 2020, Kaneka Corporation collaborated with the biomedical research institute “de Duve Institute” of the University of Louvain, wherein they signed a research collaboration agreement in order to develop innovative biomedicine production technologies and strengthen and expand the company’s current biomedicine CDMO business.
• In April 2020, Bio-Rad Laboratories, Inc. launched a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19.

The key market players covered by FMI include :

• GE Healthcare
• Thermo Fisher Scientific
• Kaneka Corporation
• JNC Corporation
• Purolite Life Sciences
• Bio-Rad Laboratories Inc.
• JSR Corporation (JSR Life Sciences LLC)
• Repligen
• Tosoh Bioscience
• Merck Group (Merck Millipore)
• Novasep Holdings SAS
• Agilent Technologies Inc.
• GenScript
• Abcam PLC (Expedeon Ltd.)
• Avantor Inc.
• Takara Bio
• PerkinElmer Inc.
• Suzhou Nanomicro Technology Co. Ltd.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1720

Protein A Resins

by Category Product:

• Natural Protein A Resin
• Recombinant Protein A Resin

Matrix:

• Agarose Based Matrix
• Glass or Silica Based Matrix
• Organic Polymer Based Matrix

Application:

• Immunoprecipitation
• Antibody Purification

End User:

• Biopharmaceutical Manufacturers
• Clinical Research Laboratories
• Academic Institutes

For instance, in the past recent years, Abbott received FDA approval for its bioresorbable heart stent absorb, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the U.S.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1993

Key Takeaways from Coronary Stents Market Study

• In terms of raw material, the coronary stents market is expected to witness substantial growth in the next few years. Currently, polymer segment accounts for major share of the global Coronary Stents market.
• North America has been estimated to dominate the coronary stents market with maximum market share in 2019.
• The primary trend in the coronary stents market is an increasing number of local manufacturers of coronary stents. Also, growth in interventional cardiology procedures, is an ongoing trend in the coronary stents market.

“Increase in number of cardiac catheterization laboratories and increasing prevalence of cardiovascular diseases are the main factors that will continue to drive the growth of the coronary stents.” says the FMI Analyst.

Increasing Manufacturing Practices across Low Cost Geographies, Boosts the Coronary Stents Market

Transfer of medical device manufacturing practices across low cost geographies such as India, China, South Africa, ASEAN and other Asian countries is expected to fuel growth of the global coronary stents market. Companies offering hospital supplies are targeting price-sensitive geographies through mergers and acquisitions. Leading manufacturers of coronary stents are acquiring domestic players to gain maximum market share in local markets. Moreover, these companies are focusing on low cost product launches in these region owing to large patient pool belonging to the lower middle income group.

Want more insights?

Coronary Stents Market, a new study from Future Market Insights, provides unparalleled insights on evolution of the Coronary Stents market during 2014 – 2018 and presents demand projections during 2020 – 2026 on the basis of product (drug eluting stents, bare metal stents and bioresorbable vascular stents), raw material (cobalt chromium, stainless steel, platinum-chromium, nickel titanium and polymer), end user (hospitals, public hospitals, private hospitals, ambulatory surgical centers and cardiac catheterization laboratories), across seven prominent regions.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1993

Key Segment

By Raw Material

• Cobalt Chromium
• Stainless Steel
• Platinum – Chromium
• Nickel – Titanium
• Polymer

By End User

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories

 More than 90% of the global market revenues for oxytocic pharmaceuticals will be harvested from the sales of oxytocic pharmaceuticals originating from synthetic sources. By the end of 2031, an estimated US$ 207.80 million revenues will be emanated from the global sales of synthetic oxytocic pharmaceuticals.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1445

Global Oxytocic Pharmaceuticals Market: Regional Analysis

The need for oxytocic pharmaceuticals in the world will always remain contingent to the rise in pregnancy incidences and birth rate. Various parts of the world exhibit diverse birth rate, which incidentally drives the growth of their oxytocic pharmaceuticals market, accordingly. In North America, oxytocic pharmaceuticals are majorly used for postpartum haemorrhage, which is one of the most-prominent indication among labouring women in the US and Canada.

However, China is expected to remain the largest market for oxytocic pharmaceuticals in the world. Considering the country’s exploding birth rate, China’s oxytocic pharmaceuticals market will be valued over US$ 55 million by 2031-end, expanding at 9.8% CAGR. In 2016, Japan’s oxytocic pharmaceuticals revenues amounted to an estimated US$ 1.7 million, while the oxytocic pharmaceuticals market in Asia-Pacific excluding Japan & China (APEJC) region has been estimated to account for nearly 20% of global revenues.

Global Oxytocic Pharmaceuticals Market: Research Highlights

• Licensing agreements for development of newer oxytocic pharmaceuticals is rampantly boosting the global market revenues, profiting local players as well as industry leaders.
• Surging prevalence of labour induction procedures for child births will continue promoting the use of oxytocic pharmaceuticals throughout the forecast period.
• The global oxytocic pharmaceuticals revenues, however, are projected to witness an inhibited growth on the account of rising preference to alternative drugs such as magnesium sulphate and misoprostol.
• India’s contribution to the APEJC oxytocic pharmaceuticals market is predicted to reach nearly 60% by the end of 2031.
• More than 22,000 thousand units of oxytocic pharmaceuticals will be sold globally for treating labour arrest over the forecast period.
• Hospitals will remain the largest end-user of oxytocic pharmaceuticals in the world, revenues from which will expand beyond 12% CAGR.
• A majority of medical professionals in the world will recommend intravenous administration of oxytocic pharmaceuticals, accounting for more than two-third of global market revenues by the end of 2031.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1445

The Report Segments the Market into Five Sections:

By Indication

• Abortion Induced Incomplete
• Inevitable Abortion
• Post-partum Haemorrhage
• Labour Induction
• Labour Arrest

By Route of administration

• Intravenous Infusion/Injection
• Intramuscular Injection

By Source of Origin

• Natural Oxytocin
• Synthetic Oxytocin Derivative

By End-User

• Hospitals
• Maternity clinics

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan and China (APEJC)
• Japan
• China
• Middle East & Africa (MEA)

Prevalence of Osteoporosis and Vitamin D deficiency Building Market – Ageing Remains Primary Catalyst

Driven primarily by rising incidences of osteoporosis and other bone-related disorders, the market will also be fuelled by the ensuing awareness about growing osteoporosis incidences. Increased emphasis on preventive healthcare, early diagnosis, and quality treatment are identified to be among the key factors spurring the demand for bone densitometer devices globally. Ageing, resulting in almost threefold risks of acquiring wrist, hip, and vertebral osteoporosis, will remain a major market growth catalyst.

Moreover, increasing prevalence of vitamin D and calcium deficiency disorders will also escalate the demand in near future. Burgeoning cancer prevalence is boosting the number of patients undergoing chemotherapy, which is further identified to affect their bone density in the long run. This will be another driver to growth of bone densitometer market. Evidently increasing integration of DXA into routine health check-ups will also escalate market growth over the forecast period.

Developed Markets Marching Ahead, Asian Countries to Witness Robust Growth

North America will continue to represent the largest market for bone densitometer devices, followed by Western Europe and Asia Pacific. Latin America and MEA will witness relatively lower growth rates.

• The U.S. will continue to dominate North American market with nearly 75% revenue share of the region and by 2026, North America is expected to surpass a value of US$ 204 Mn, grabbing over half of the market revenue share.
• APEJ will be the most lucrative, fastest growing market for bone densitometer devices. Led by China, followed by India and ANZ, this region will approach US$ 61 Mn in 2026, expanding at CAGR of 4.2% over 2016-2026. The Chinese market for bone densitometer devices is expected to exceed US$ 20 Mn in revenues, whereas India’s revenues are estimated at over US$ 17 Mn by 2026 end.

Product-wise Segmentation

By product, the global consumption of axial bone densitometer will possibly account for the revenues of US$ 272.3 Mn in 2026. This segment will grow at an estimated 3.7% of CAGR, gaining over 150 BPS during 2016-2026 against peripheral bone densitometer segment. Axial bone densitometer devices will continue to gain higher traction due to superior accuracy and precision, accounting for around 70% value share by 2026. Peripheral bone densitometer segment is also likely to witness steady adoption, as it allows short scan time and lesser exposure to radiation.

Technology-wise Segmentation

Based on technology, dual energy X-ray absorptiometry (DXA) segment is expected to remain dominant with nearly 65% share by 2026 end. This segment will possibly attain a value worth US$ 253 Mn in 2026, expanding at the highest CAGR of 3.7%. Quantitative ultrasound (QUS) segment is anticipated to register a 3.2% of CAGR, reaching over US$ 88 Mn by 2026 end.

End-user-wise Segmentation

In terms of end-user, hospitals segment will remain the largest consumer of bone densitometer devices, accounting for revenues worth US$ 252.3 Mn in 2026. Diagnostic centres, the second largest end-user segment with an estimated value of around US$ 80 Mn by 2026, is expected to witness the highest CAGR of 3.8% over the forecast period. Hospitals are likely to capture around 65% share in 2026, whereas diagnostic centres will bag over 20% share in 2026 market revenues.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-733

Beetling Trends and Upcoming Opportunities Fostering Demand for Bone Densitometer Devices

Increasing adoption of DXA, coupled with growing prominence of ultrasound technology, will be important trends in market. Improving healthcare infrastructure and extended reimbursement for osteoporosis treatment are also highlighted as influential trends. While flourishing medical tourism initiatives will remain a growing trend, strategic M&A activities will continue to trend among key players.

Manufacturers are likely to witness several untapped opportunities in developing Asian markets, which are primarily driven by exploding population and immense healthcare burden. Governments are also increasingly supporting the market through favourable bone density measurement awareness programs.